MARC details
| 000 -LEADER |
|---|
| fixed length control field |
06388namaa22004211i 4500 |
| 003 - CONTROL NUMBER IDENTIFIER |
|---|
| control field |
OSt |
| 005 - أخر تعامل مع التسجيلة |
|---|
| control field |
20250223033348.0 |
| 008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION |
|---|
| fixed length control field |
241218s2023 |||a|||f m||| 000 0 eng d |
| 040 ## - CATALOGING SOURCE |
|---|
| Original cataloguing agency |
EG-GICUC |
| Language of cataloging |
eng |
| Transcribing agency |
EG-GICUC |
| Modifying agency |
EG-GICUC |
| Description conventions |
rda |
| 041 0# - LANGUAGE CODE |
|---|
| Language code of text/sound track or separate title |
eng |
| Language code of summary or abstract |
eng |
| -- |
ara |
| 049 ## - Acquisition Source |
|---|
| Acquisition Source |
Deposit |
| 082 04 - DEWEY DECIMAL CLASSIFICATION NUMBER |
|---|
| Classification number |
615.1 |
| 092 ## - LOCALLY ASSIGNED DEWEY CALL NUMBER (OCLC) |
|---|
| Classification number |
615.1 |
| Edition number |
21 |
| 097 ## - Degree |
|---|
| Degree |
M.Sc |
| 099 ## - LOCAL FREE-TEXT CALL NUMBER (OCLC) |
|---|
| Local Call Number |
Cai01.08.08.M.Sc.2023.As.F |
| 100 0# - MAIN ENTRY--PERSONAL NAME |
|---|
| Authority record control number or standard number |
Ashraf Kassem Abd El-Karim Rizk, |
| Preparation |
preparation. |
| 245 10 - TITLE STATEMENT |
|---|
| Title |
Formulation and evaluation of corticosteroid in certain buccal dosage form for local treatment / |
| Statement of responsibility, etc. |
by Ashraf Kassem Abd El-Karim Rizk ; Supervision of Prof. Dr. Mohamed Ahmed El-Nabarawi, Prof. Dr. Hanan Mohamed Kamal Refai. |
| 246 15 - VARYING FORM OF TITLE |
|---|
| Title proper/short title |
/ صياغة وتقييم عقار كورتيكوستيرويد في بعض المستحضرات الفمية للعلاج الموضعى فى الفم |
| 264 #0 - PRODUCTION, PUBLICATION, DISTRIBUTION, MANUFACTURE, AND COPYRIGHT NOTICE |
|---|
| Date of production, publication, distribution, manufacture, or copyright notice |
2023. |
| 300 ## - PHYSICAL DESCRIPTION |
|---|
| Extent |
116 pages : |
| Other physical details |
illustrations ; |
| Dimensions |
25 cm. + |
| Accompanying material |
CD. |
| 336 ## - CONTENT TYPE |
|---|
| Content type term |
text |
| Source |
rda content |
| 337 ## - MEDIA TYPE |
|---|
| Media type term |
Unmediated |
| Source |
rdamedia |
| 338 ## - CARRIER TYPE |
|---|
| Carrier type term |
volume |
| Source |
rdacarrier |
| 502 ## - DISSERTATION NOTE |
|---|
| Dissertation note |
Thesis (M.Sc.)-Cairo University, 2023. |
| 504 ## - BIBLIOGRAPHY, ETC. NOTE |
|---|
| Bibliography, etc. note |
Bibliography: pages 106-116. |
| 520 ## - SUMMARY, ETC. |
|---|
| Summary, etc. |
Corticosteroids are often recommended as first-line treatment for recurrent aphthous ulcers because they affect recurrent aphthous ulcers (RAU) by blocking the effect of T-lymphocyte-epithelial cell interaction, reducing inflammation and subsequent ulceration.<br/>Prednisolone metasulfo benzoate (PMB) is a synthetic glucocorticoid with anti-inflammatory and immunomodulating properties. It also activates specific nuclear receptors resulting in an altered gene expression and inhibition of proinflammatory cytokine production. Furthermore, it decreases the number of circulating lymphocytes and induces cell differentiation. Moreover, PMB provides topical or local anti-inflammatory effects with reduced systematic corticosteroid concentration compared to prednisolone. Therefore, developing a topical delivery system that maximizes PMB localization in the mucosal epithelium tissues is highly beneficial for more efficient treatment of RAU.<br/>Nanoparticles provide numerous advantages for buccal drug delivery as they enhance the solubility of poorly soluble drugs and consequently improve drug dissolution rates; also, they may provide controlled drug release. Moreover, the nanoparticles can enhance the stability of active ingredients. Furthermore, the use of cationic nanoparticles in the buccal route has been studied extensively for improving buccal drug delivery as cationic nanocarriers interact with the negatively charged mucosa, causing improvement in surface binding; thus, they can prolong the drug residence time and consequently enhance drug absorption into the mucosal tissues.<br/>Quatsomes (QS) are unilamellar nanoscopic vesicles composed of sterol and quaternary ammonium surfactants (QAS). Quatsomes have excellent stability, homogeneity, and high drug-loading capacity. Also, quatsomes enhance the specific bioactivity of proteins and protect them from degradation in pharmaceutical formulations. Furthermore, quatsomes can be labeled with fluorescent dyes for bioimaging and biodistribution assays. Therefore, quatsomes are considered promising alternatives to conventional liposomes. Furthermore, due to the presence of QAS, such as cetyltrimethylammonium bromide (CTAB), in the components of quatsomes, it possesses antimicrobial activity, which is considered beneficial in treating wounds.<br/>This study aims to formulate a buccal mucoadhesive gel containing prednisolone metasulfo benzoate loaded quatsomes for efficient localized therapy of recurrent aphthous ulcers to avoid systemic adverse effects accompanied by its oral administration. |
| 520 ## - SUMMARY, ETC. |
|---|
| Summary, etc. |
• تقرحات الفم المتكررة تجعل من الصعب على المرضى المضغ والتحدث والابتلاع و يترواح حجمها من أقل من 1 ملم إلى أكثر من 1 سم وتتصف بمجموعة متنوعة من القرح البيضاوية الشكل التي تحدث بشكل متكرر مع غشاء كاذب مصفر على أرضية القرحة وحدودها.معدل تكرارها يصل إلى 50% بعد ثلاثة أشهر، يمكن أن تؤثر هذه القرح على ما يصل إلى 25% من عامة السكان. وبالمقارنة مع الرجال، فإن النساء أكثر عرضة للإصابة بهذه الحالة.<br/>• بريدنيزولون ميتا سلفوبنزوات هو أحد أكثر أدوية الكورتيكوستيرويدات المضادة للالتهابات والمعدلة للمناعة.يستخدم في علاج الأمراض الالتهابية المزمنة ويستخدم موضعياً في المرضى الذين يعانون من التهاب القولون التقرحي.<br/>• و لذلك فان العمل الحالى يهدف الى تطوير الحويصلات النانونية المرنه (الكوتسومات) محمله بدواء بريدنيزولون ميتا سلفوبنزوات لتعاطيه عن طريق التجويف الفمى لتحقيق الشفاء السريع والكامل لتقرحات الفم.<br/>• قد يؤدى استخدام العقار عن طريق وصوله الى الدم الى بعض الآثار الجانبية مثل اضطراب الكلى واضطرابات العضلات والعظام عند استخدامة لعلاج قرح الفم. ولذلك تم تطويرنظام توصيل موضعي قادر على دخول العقار داخل الانسجة بشكل موضعي و الحفاظ على خروج العقار فى الانسجة بشكل ممتد لتحقيق الشفاء السريع وتجنب الآثار الجانبية . |
| 530 ## - ADDITIONAL PHYSICAL FORM AVAILABLE NOTE |
|---|
| Issues CD |
Issues also as CD. |
| 546 ## - LANGUAGE NOTE |
|---|
| Text Language |
Text in English and abstract in Arabic & English. |
| 650 #7 - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name entry element |
Durgs |
| Source of heading or term |
qrmak |
| 653 #0 - INDEX TERM--UNCONTROLLED |
|---|
| Uncontrolled term |
Buccal mucoadhesive gel |
| -- |
prednisolone sodium metazoate |
| -- |
quatsomes |
| -- |
recurrent aphthous ulcer |
| 700 0# - ADDED ENTRY--PERSONAL NAME |
|---|
| Personal name |
Mohamed Ahmed El-Nabarawi |
| Relator term |
thesis advisor. |
| 700 0# - ADDED ENTRY--PERSONAL NAME |
|---|
| Personal name |
Hanan Mohamed Kamal Refai |
| Relator term |
thesis advisor. |
| 900 ## - Thesis Information |
|---|
| Grant date |
01-01-2023 |
| Supervisory body |
Mohamed Ahmed El-Nabarawi |
| -- |
Hanan Mohamed Kamal Refai |
| Universities |
Cairo University |
| Faculties |
Faculty of Pharmacy |
| Department |
Department of Pharmaceutics and Industrial Pharmacy |
| 905 ## - Cataloger and Reviser Names |
|---|
| Cataloger Name |
Shimaa |
| Reviser Names |
Huda |
| 942 ## - ADDED ENTRY ELEMENTS (KOHA) |
|---|
| Source of classification or shelving scheme |
Dewey Decimal Classification |
| Koha item type |
Thesis |
| Edition |
21 |
| Suppress in OPAC |
No |